Alzinova Team

Chief Executive Officer since 2019

Kristina has 30 years of experience in drug development from leading roles in the pharmaceutical and biopharma industry. She has previously worked at AstraZeneca with research and development in both early and late phase and has been globally responsible for marketed products. Kristina has also worked at the biopharma company Albireo AB/Pharma Inc, as VP Clinical & Regulatory Affairs and VP Global Project Head and was engaged in building the company.

Shareholdings and warrants:
6 000 shares
Warrants granting acquisition rights to:
53 000 shares (2020/2023, incentive program)

Education: MSc Pharmacy, PhD in Clinical Pharmacology

Other assignments: Board member of GU Ventures

Chief Scientific Officer since 2015

Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on protein stability and folding. Anders has since 2007 worked with neurotoxic peptide aggregates, which led to the development of ALZ-101 and ALZ-201. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.

Shareholdings and warrants:
185 193 shares
Warrants granting acquisition rights to:
10 500 shares (2020/2023, incentive program)

Education: PhD in Chemistry

Other assignments: –

Chief Financial Officer since 2020

Håkan has 20 years of experience from leading finance positions in the shipping industry. He has previously worked as CFO and CEO at a privately owned Swedish shipping company with international operations where he has been involved in building the company. Håkan worked as CFO for Safe at Sea AB. Håkan also works as financial consultant for small and medium-sized companies.

Shareholdings and warrants:
6 000 shares
Warrants granting acquisition rights to:
21 000 shares (2020/2023, incentive program)

Education: BSc Business and Economics, Small business management

Other assignments: –

Chief Medical Officer since 2019

Anders has more than 25 years of experience in drug development in both preclinical and phase I-IV clinical studies, as well as registration work on intra-EU approved medicines. He has worked at MSD Sweden, held leading positions at AstraZeneca and as Senior Global Director at Boehringer Ingelheim GmbH & Co KG in Germany, medically leading a large number of cardiovascular projects at various stages.

Shareholdings and warrants: –

Education: Licensed Physician, specialist in thoracic surgery. Associate Professor and Doctor of Medicine.

Other assignments: CMO, Aptahem AB (publ)

Intellectual Property Officer since 2021

Ann-Sofie Sternås has more than 25 years of experience in IP/patent matters from the pharmaceutical industry. She has an in-depth understanding and knowledge of IP strategic matters, with a heavy focus on the US legislation, particularly IP matters in the interface between patent legislation and regulatory law. Ann-Sofie has previously worked at AstraZeneca and Pharmacia on IP-related matters from a global perspective, including more than 10 years in the IP litigation of several blockbuster drugs. She has also worked at the investment company Karolinska Development AB.

Shareholdings and warrants: –

Education: Authorized European Patent Attorney; Authorized Swedish Patent Attorney. M. Sc. Chemistry education from Royal Institute of Technology

Other assignments: Head of IP in several Swedish pharma/biotech companies.

Development Project Director since 2021

Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond. Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies

Shareholdings and warrants:
900 shares

Education: MSc Chemical Engineering, PhD Molecular Biology

Other assignments: CEO, ESP Life Science Consulting AB

Communications Specialist since 2021

Jamie has 25 years of experience of leadership communications in the life science and technology industries. In addition to his role at Alzinova, Jamie heads up communications at AstraZeneca’s innovation hub, the BioVentureHub. Previous employers include AstraZeneca, Mölnlycke Healthcare, Nobel BioCare, Ericsson and Spotify. Jamie also works as a consultant for small and medium-sized companies.

Shareholdings and warrants:
5 000 shares (through company) and 0 warrants

Education: BSc (Hons) French and European Studies

Other assignments: Chief Communications Officer, AstraZeneca BioVentureHub

Executive Assistant & Communications since 2020

Cecilia has over 10 years of experience in the biopharma industry and more than 20 years in administration.

Shareholdings and warrants: –